-
YMAB Dashboard
- Financials
- Filings
-
Holdings
- Transcripts
- ETFs
- Insider
- Institutional
- Shorts
Y-mAbs Therapeutics (YMAB)
Company Profile
Quarter (USD) | Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 68.12 mm | 68.12 mm | 68.12 mm | 68.12 mm | 68.12 mm | 68.12 mm |
Cash burn (monthly) | 3.23 mm | 1.54 mm | 2.86 mm | 2.37 mm | 3.56 mm | 1.82 mm |
Cash used (since last report) | 16.40 mm | 7.81 mm | 14.51 mm | 12.05 mm | 18.06 mm | 9.26 mm |
Cash remaining | 51.72 mm | 60.31 mm | 53.61 mm | 56.07 mm | 50.06 mm | 58.86 mm |
Runway (months of cash) | 16.0 | 39.2 | 18.8 | 23.6 | 14.1 | 32.3 |
13F holders | Current |
---|---|
Total holders | 115 |
Opened positions | 18 |
Closed positions | 12 |
Increased positions | 38 |
Reduced positions | 32 |
13F shares | Current |
---|---|
Total value | 224.08 bn |
Total shares | 40.41 mm |
Total puts | 900.00 |
Total calls | 5.60 k |
Total put/call ratio | 0.2 |
Largest owners | Shares | Value |
---|---|---|
Biotech ApS WG | 4.56 mm | $57.17 mm |
Paradigm Biocapital Advisors | 4.24 mm | $33.17 bn |
HBM Healthcare Investments | 3.30 mm | $41.35 mm |
BlackRock | 3.00 mm | $23.48 bn |
Acorn Capital Advisors | 2.86 mm | $22.41 bn |
Sofinnova Investments | 2.19 mm | $17.18 bn |
Sofinnova Venture Partners X | 2.19 mm | $52.07 mm |
Vanguard | 2.00 mm | $15.66 bn |
Polar Capital | 1.83 mm | $14.34 bn |
Caligan Partners | 1.77 mm | $13.84 bn |
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
17 Jan 25 | John LaRocca | Common Stock | Grant | Acquire A | No | No | 0 | 21,500 | 0.00 | 21,500 |
17 Jan 25 | John LaRocca | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 6.16 | 42,900 | 264.26 k | 42,900 |
17 Jan 25 | Michael J Rossi | Common Stock | Grant | Acquire A | No | No | 0 | 105,300 | 0.00 | 141,000 |
17 Jan 25 | Michael J Rossi | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 6.16 | 210,700 | 1.30 mm | 210,700 |
17 Jan 25 | Joris Wilms | Common Stock | Grant | Acquire A | No | No | 0 | 21,500 | 0.00 | 52,100 |
17 Jan 25 | Joris Wilms | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 6.16 | 42,900 | 264.26 k | 42,900 |
17 Jan 25 | Douglas J Gentilcore | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 6.16 | 142,600 | 878.42 k | 142,600 |
17 Jan 25 | Thomas Gad | Common Stock | Grant | Acquire A | No | No | 0 | 32,000 | 0.00 | 213,531 |
17 Jan 25 | Thomas Gad | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 6.16 | 64,000 | 394.24 k | 64,000 |